SUPERNUS PHARMACEUTICALS, INC.SUPN

SUPERNUS PHARMACEUTICALS, INC. Revenue Disclosure

10-KFiled Feb 25, 20252 min read
Disaggregated Revenues
The following table provides information regarding total revenues (dollars in thousands):
 Year Ended December 31,
 202420232022
Net product sales   
Qelbree$241,273 $140,192 $61,322 
GOCOVRI130,824 119,637 104,421 
Oxtellar XR99,464 113,404 115,345 
APOKYN73,926 75,083 75,305 
Trokendi XR63,201 94,336 261,221 
Other(1)
29,008 31,281 31,818 
Total net product sales637,696 573,933 649,432 
Royalty, licensing and other revenues24,121 33,588 17,806 
Total revenues$661,817 $607,521 $667,238 
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
In December 2023, the Company submitted to the FDA a notification of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024.
The Company recognized noncash royalty revenues of $4.0 million, and $9.8 million for the years ended December 31, 2023 and 2022, respectively. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023 (see Note 2, Summary of Significant Accounting Policies).
Adjustments related to prior year sales in 2024 was less than 3% of net product sales. The majority of the adjustment is attributable to Qelbree, reflecting favorable actual returns experienced in 2024. As a result, the Company changed its estimated provision for product returns based on the most recent experience. In 2023 and 2022, adjustments related to prior year sales have amounted to less than 1% of net product sales for each of the respective periods.
The following table shows the percentage of net product sales to total net product sales:
Percentage of Net Product Sales
Year Ended December 31,
202420232022
Qelbree38%24%9%
GOCOVRI20%21%16%
Oxtellar XR16%20%18%
APOKYN12%13%12%
Trokendi XR10%16%40%
Other(1)
4%6%5%
Total100%100%100%
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Free Sentinel

Want the next SUPERNUS PHARMACEUTICALS, INC. revenue disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment SUPERNUS PHARMACEUTICALS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesSegmentsCommitmentsStock CompensationNew Standards